OOIR: Observatory of International Research

Papers

(The TQCC of Lancet HIV is 7. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-09-01 to 2025-09-01.)

Article	Citations
Transplant donation without discrimination	256
How do we prevent anal cancer in people living with HIV?	142
Argentina updates HIV laws	139
Evidence supports use of on-demand PrEP for HIV prevention	138
How much could long-acting PrEP cost in South Africa?	135
The Australian AIDS crisis through the eyes of volunteers	134
Correction to Lancet HIV 2022; 9: e791–800	133
HIV and COVID-19: juxtaposition of two pandemics	108
Rapid access to antiretroviral therapy, receipt of naltrexone, and strengths-based case management versus standard of care for HIV viral load suppression in people with HIV who inject drugs in Russia	105
Optimising anal cancer screening through risk stratification	101
Controversial chronicler of LGBTQ rights	97
Dolutegravir dosing for children with HIV weighing less than 20 kg: pharmacokinetic and safety substudies nested in the open-label, multicentre, randomised, non-inferiority ODYSSEY trial	95
Scaling up access to HIV pre-exposure prophylaxis (PrEP): should nurses do the job?	86
Steps toward quick and equitable roll-out of lenacapavir	82
Risk estimation in HIV reveals our usual blind spots	82
Are we ready for long-acting HIV treatment for adolescents?	79
Free HIV self-test for identification and linkage to care of previously undetected HIV infection in men who have sex with men in England and Wales (SELPHI): an open-label, internet-based, randomised c	76
Safety, tolerability, and pharmacokinetics of an annual tenofovir alafenamide silicone subdermal implant in South African women: a two-part, randomised, placebo-controlled, double-blind, first-in-huma	72
Lenacapavir: an attractive option, but proceed with caution	72
Standard-dose versus double-dose dolutegravir in HIV-associated tuberculosis in South Africa (RADIANT-TB): a phase 2, non-comparative, randomised controlled trial	71
Lung cancer in people living with HIV	64
A moment of reckoning	63
Redefining care: injectable HIV treatment for adolescents	59
All roads lead to Westminster: the infected blood scandal	57
Unheard testimony	53

Fate of people with HIV in jeopardy in Ukraine	52
Gains and gaps: addressing HIV in diverse sex worker groups	52
Stigma reduction is key to improving the HIV care continuum	50
Game-changing study of second-line HIV treatment	49
Reducing HIV transmission in British Columbia, Canada	47
Recent gay Black history in the UK	46
HIV care cascade and associated factors among men who have sex with men, transgender women, and genderqueer individuals in Zimbabwe: findings from a biobehavioural survey using respondent-driven sampl	46
HIV treatment-as-prevention and its effect on incidence of HIV among cisgender gay, bisexual, and other men who have sex with men in Australia: a 10-year longitudinal cohort study	45
Suicide prevention research is crucial to achieving health equity for people with HIV	44
Outcomes of people living with HIV after hospital discharge: a systematic review and meta-analysis	44
The contribution of intimate partner violence to vertical HIV transmission: a modelling analysis of 46 African countries	43
Lateral flow assay-based CD4 cell count testing for advanced HIV disease	42
Sex as a biological variable in HIV-1 and schistosome co-infection	42
Dolutegravir plus boosted darunavir versus recommended standard-of-care antiretroviral regimens in people with HIV-1 for whom recommended first-line non-nucleoside reverse transcriptase inhibitor ther	42
Equitable access to long-acting PrEP on the way?	42
A public health approach to drug use crucial to ending AIDS	40
Making America unhealthy again	39
Safety and immunogenicity of investigational tuberculosis vaccine M72/AS01E–4 in people living with HIV in South Africa: an observer-blinded, randomised, controlled, phase 2 trial	39
Risk factors for COVID-19-related in-hospital mortality in a high HIV and tuberculosis prevalence setting in South Africa: a cohort study	38
Integration of sexual health and HIV services	38
More evidence for worse COVID-19 outcomes in people with HIV	37
Establishing shared definitions of virological failure and discontinuation for long-acting injectable cabotegravir and rilpivirine therapy (the CONSENSUS-LAI Study): an international survey and Delphi	37
WHO recommends lenacapavir for HIV prevention	36
Healing the stigma of HIV/AIDS	35
Patterns of post-partum HIV care engagement	35
Connie Norman: a warm tribute to a forgotten AIDS activist	35
PEPFAR: promises and pitfalls	34
Eliminating HIV in the UK among men who have sex with men	34
HIV incidence and impact of interventions among female sex workers and their clients in the Middle East and north Africa: a modelling study	33
An eventful conference	33
Use of WHO paediatric weight-band dosing in drug labels	33
Living with COVID-19 and preparing for future pandemics: revisiting lessons from the HIV pandemic	32
HIV self-testing: from availability to strategic deployment	32
Lifestyle modification programme for people living with HIV with metabolic dysfunction-associated steatotic liver disease: a randomised controlled trial	32
Improving health equity and ending the HIV epidemic in the USA: a distributional cost-effectiveness analysis in six cities	32
Preventing sexually transmitted infections in the age of PrEP	32
Risks and benefits of oral HIV pre-exposure prophylaxis for people with chronic hepatitis B	31
Moving beyond hotspots of HIV prevalence to geospatial hotspots of UNAIDS 95-95-95 targets in sub-Saharan Africa	31
Lesotho's progress towards UNAIDS 95-95-95 targets from 2016 to 2020: comparison of Population-based HIV Impact Assessments	30
How can Africa sustain its HIV response amid US aid cuts?	30
Relative cost-effectiveness of long-acting injectable cabotegravir versus oral pre-exposure prophylaxis in South Africa based on the HPTN 083 and HPTN 084 trials: a modelled economic evaluation and th	29
Advancing the prevention and treatment of HIV in children: priorities for research and development	28
Trends in HIV testing, the treatment cascade, and HIV incidence among men who have sex with men in Africa: a systematic review and meta-analysis	28
Reduction in mortality from HIV-related CNS infections in routine care in Africa (DREAMM): a before-and-after, implementation study	27
Reduction of HIV reservoir after stem cell transplantation	27
HIV-free generation within reach for Botswana	27
Highlights from the 25th International AIDS Conference	26
Can treatment-as-prevention and PrEP reduce HIV incidence?	26
Addressing partner violence to end infant HIV infection	26
Thank you to The Lancet HIV's statistical and peer reviewers in 2023	26

Closing the gap to UNAIDS 95-95-95: Lesotho's success story	25
Effects of self-testing on HIV outcomes in west Africa	25
Implementation of PrEP in Latin America	25
Second-line HIV treatments for adults in LMICs	24
Coffee with IAS President Beatriz Grinsztejn	24
Crucial need for improved pharmacovigilance in pregnancy	23
Cognitive performance, neuropsychiatric symptoms, and cerebrospinal fluid viral control following programmatic switch from efavirenz-based to dolutegravir-based antiretroviral therapy in South Africa	23
Effects of clinical, comorbid, and social determinants of health on brain ageing in people with and without HIV: a retrospective case-control study	22
The HIV care continuum for sexually active transgender women in three metropolitan municipalities in South Africa: findings from a biobehavioural survey 2018–19	22
No woman left behind: achieving cervical cancer elimination among women living with HIV	22
Estimates of the prevalence of undiagnosed HIV among children living with HIV in Eswatini, Lesotho, Malawi, Namibia, Tanzania, Zambia, and Zimbabwe from 2015 to 2017: an analysis of data from the cros	22
Intersectional climate justice, health equity, and HIV	21
Metabolic implications and safety of dolutegravir use in pregnancy	21
Pharmacokinetics and safety of dolutegravir in children receiving rifampicin tuberculosis treatment in South Africa (ORCHID): a prospective cohort study	21
A 4-days-on and 3-days-off maintenance treatment strategy for adults with HIV-1 (ANRS 170 QUATUOR): a randomised, open-label, multicentre, parallel, non-inferiority trial	21
Post-exposure prophylaxis to prevent HIV: new drugs, new approaches, and more questions	21
The HIV vaccine quest: ethical and implementation challenges	20
Efficacy of dolutegravir plus lamivudine in treatment-naive people living with HIV without baseline drug-resistance testing available (D2ARLING): 48-week results of a phase 4, randomised, open-label,	20
Optimised second-line regimens in the public health approach	20
Need for clear inclusion criteria in reviews of antiretroviral treatments	20
Long-acting cabotegravir and rilpivirine dosed every 2 months in adults with HIV-1 infection (ATLAS-2M), 96-week results: a randomised, multicentre, open-label, phase 3b, non-inferiority study	20
Treatment of HIV and HBV coinfection	19
Breast cancer survival in women living with HIV	19
Dolutegravir twice-daily dosing in children with HIV-associated tuberculosis: a pharmacokinetic and safety study within the open-label, multicentre, randomised, non-inferiority ODYSSEY trial	18
Point-of-care testing to achieve paediatric 95-95-95 targets	18
Complex response to HIV and tuberculosis in South Sudan	18
Can COVID-19 changes reduce stigma in African HIV clinics?	18
Dolutegravir drug-resistance monitoring in Africa	17
Integrase inhibitors hand us a new HIV clinical puzzle	17
Adolescent retention in HIV care within differentiated service-delivery models in sub-Saharan Africa	17
Making PrEP easy	17
Trends in suicide mortality among people with HIV after diagnosis during 2012–18: a retrospective, national cohort study in China	17
Efficacy and safety of long-acting cabotegravir compared with daily oral tenofovir disoproxil fumarate plus emtricitabine to prevent HIV infection in cisgender men and transgender women who have sex w	17
Identifying risk factors for anal cancer in people with HIV in Spain: a multicentre retrospective cohort study nested in the PISCIS cohort	17
The future of HIV pre-exposure prophylaxis adherence: reducing barriers and increasing opportunities	17
Thank you to The Lancet HIV's clinical and statistical peer reviewers in 2021	16
Paying tribute to a generation devastated by HIV/AIDS	16
Realising long-acting ART as first-line treatment	16
HERO—providing support for those engaged in chemsex	16
Non-communicable diseases in older people living with HIV in four African countries: a cohort study	15
HIV treatment in Russia on the brink of crisis	15
Effects of antiretrovirals on major adverse cardiovascular events in the REPRIEVE trial: a longitudinal cohort analysis	15
Long-acting PrEP for adolescent girls and young women	15
A new index to guide global drug policies	15
Critical illness due to infection in people living with HIV	14
Viral suppression and HIV-1 drug resistance 1 year after pragmatic transitioning to dolutegravir first-line therapy in Malawi: a prospective cohort study	14
Activists step in to deliver PEP and PrEP in Mexico	14
Unified health surveys for integrated health systems	14
Epidemiology of severe COVID-19 from South Africa	14
Initiation and continued use of oral pre-exposure prophylaxis among pregnant and postpartum women in South Africa (PrEP-PP): a demonstration cohort study	14
Safety and immunogenicity of CoronaVac in people living with HIV: a prospective cohort study	14
Dolutegravir and pregnancy outcomes including neural tube defects in the USA during 2008–20: a national cohort study	14
HIV-related CNS infections: translating DREAMM into reality	13
Ending HIV in Chicago by 2030	13
PEPFAR reauthorisation hangs in the balance	13
Improving outcomes for children in families with HIV	13
Zvandiri—when medicines alone are not enough	13
Correction to Lancet HIV 2023; 10: e424–26	13
Tajikistan faces a crucial moment in HIV/AIDS response	13
Inherited fear: 40 years of HIV/AIDS in the UK	13
A career dedicated to public service	13
Forgiveness of an intermittent HIV treatment strategy	13
HIV viral suppression is key to healthy longevity	13
Correction to Lancet HIV 2025; 12: e473–84	12
Immunological and virological findings in a patient with exceptional post-treatment control: a case report	12
Expanding options of child-friendly, single-tablet regimens for young children with HIV	12
Reimagining HIV prevention with artificial intelligence	12
Trauma-informed HIV prevention for forcibly displaced adolescents and young adults	12
Changes in bodyweight after initiating antiretroviral therapy close to HIV-1 seroconversion: an international cohort collaboration	12
Expanding PrEP treatment options with a potent anti-HIV antibody	12
Increased risk of mental illness in people with HIV	12
HIV incidence estimation among female sex workers in South Africa: a multiple methods analysis of cross-sectional survey data	12
Long-acting PrEP: new opportunities with some drawbacks	11
Home delivery of ART: could this be a reality in South Africa?	11
Where does doravirine fit in current antiretroviral therapy?	11
Outdated attitudes to HIV must change	11
Thank you to The Lancet HIV's statistical and peer reviewers in 2022	11
Screening for chlamydia and incidence of symptomatic infections	11
Real-world safety of pre-exposure prophylaxis for HIV	11
Response to Thailand's commitment to support community-led HIV services	11

Equitable access to PrEP is essential to reap its benefits	11
UK and US militaries update HIV policies	11
COVID-19 antivirals must not affect HIV drug supply	11
Projected outcomes of universal testing and treatment in a generalised HIV epidemic in Zambia and South Africa (the HPTN 071 [PopART] trial): a modelling study	10
Paediatric abacavir–lamivudine fixed-dose dispersible tablets and ritonavir-boosted lopinavir granules in neonates exposed to HIV (PETITE study): an open-label, two-stage, single-arm, phase 1/2, pharm	10
Observed CD4 counts at entry into HIV care and at antiretroviral therapy prescription by age in the USA, 2004–18: a cohort study	10
Putting people first in communication about HIV	10
Potential population-level effects of HIV self-test distribution among key populations in Côte d'Ivoire, Mali, and Senegal: a mathematical modelling analysis	10
Reassessing oral lead-in for injectable long-acting HIV therapy	10
Defining principles for a choice-based approach to HIV prevention	10
Mexican perspective on the Mosaico HIV vaccine trial	10
What future for HIV vaccines?	10
Ending AIDS as a public health threat: the imperative for clear messaging on U=U, viral suppression, and zero risk	10
Effectiveness of bi-monthly long-acting injectable cabotegravir and rilpivirine as maintenance treatment for HIV-1 in the Netherlands: results from the Dutch ATHENA national observational cohort	9
The urgent need for opioid agonist treatment in Russia	9
Efficacy and safety of the novel capsid inhibitor lenacapavir to treat multidrug-resistant HIV: week 52 results of a phase 2/3 trial	9
Expansion of PrEP and PEP services in China	9
It is time to act on ageing	9
Maintenance therapy with dolutegravir and lamivudine versus bictegravir, emtricitabine, and tenofovir alafenamide in people with HIV (PASO-DOBLE): 48-week results from a randomised, multicentre, open-	9
Longitudinal trends in causes of death among adults with HIV on antiretroviral therapy in Europe and North America from 1996 to 2020: a collaboration of cohort studies	9
Documenting Brazil's battle with HIV/AIDS	9
COP27 Climate Change Conference: urgent action needed for Africa and the world	8
Association of life-course events with predictors of HIV risk behaviour and HIV acquisition in Manicaland, Zimbabwe: a longitudinal analysis of a population cohort	8
Elton John AIDS Foundation plugging gaps in HIV funding	8
So many harms, so little benefit: a global review of the history and harms of HIV criminalisation	8
Low-cost point-of-care urine test to enhance PrEP adherence	8
A community-based child health and parenting intervention to improve child HIV testing, health, and development in rural Lesotho (Early Morning Star): a cluster-randomised, controlled trial	8
Longitudinal evolution of the HIV effective reproduction number following sequential expansion of treatment as prevention and pre-exposure prophylaxis in British Columbia, Canada: a population-level p	8
Protease inhibitor-based antiretroviral therapy in pregnancy: effects on hormones, placenta, and decidua	8
Legislation threat to services for LGBTQ+ people in Georgia	8
Acceptability, feasibility, and effectiveness of caregiver-assisted HIV self-testing among children using an oral mucosal test in Uganda and Zambia: a prospective interventional study	8
Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 in people living with and without HIV in South Africa: an interim analysis of a randomised, double-blind, placebo-	8
Use of mobile phone data in HIV epidemic control	8
Immunology of infants who are HIV-exposed uninfected in the parental combination antiretroviral therapy era	7
Mental health needs of adolescents with HIV in Africa	7
Social media helping younger adults combat HIV stigma	7
Dolutegravir dosing with rifampicin	7
HIV epidemiology in the WHO Eastern Mediterranean region: a multicountry programme review	7
Immunogenicity and safety of a SARS-CoV-2 recombinant spike protein nanoparticle vaccine in people living with and without HIV-1 infection: a randomised, controlled, phase 2A/2B trial	7
Due south: navigating volatile health research landscapes	7
Addressing the evidence gap for HIV prevention in pregnancy	7
CD4 cell counts at HIV diagnosis in the Eastern Mediterranean Region	7
Switch to fixed-dose doravirine (100 mg) with islatravir (0·75 mg) once daily in virologically suppressed adults with HIV-1 on bictegravir, emtricitabine, and tenofovir alafenamide: 48-week results of	7
Safety, tolerability, pharmacokinetics, and immunological activity of dual-combinations and triple-combinations of anti-HIV monoclonal antibodies PGT121, PGDM1400, 10-1074, and VRC07-523LS administere	7
Do we need routine integrase resistance testing before starting antiretroviral therapy?	7
Closeted life of a Hollywood giant	7
Efficacy and safety of three antiretroviral therapy regimens for treatment-naive African adults living with HIV-2 (FIT-2): a pilot, phase 2, non-comparative, open-label, randomised controlled trial	7